• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Healthcare·PME.AX
Share

Pro Medicus Limited Stocks

A$ 181.04Last Updated 14.08.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

A$ 13.01B

A$ 181.04
Key Takeaways

Risk factor

Limited default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1983 and based in Richmond, Australia, Pro Medicus Limited is a leading provider of medical imaging software and services. The company develops and delivers advanced solutions to hospitals, diagnostic imaging groups, and other healthcare organizations across Australia, North America, and Europe. Their core offerings include proprietary Radiology Information Systems (RIS), which streamline practice management and come with comprehensive support, training, installation, and professional services. Pro Medicus also operates Promedicus.net, an e-health platform, and supplies sophisticated imaging software designed to provide radiologists and clinicians with powerful visualization capabilities for 2D, 3D, and 4D medical images. This suite of tools is further enhanced by Picture Archiving and Communication System (PACS)/digital imaging software and integration products. Additionally, they offer mobile applications like Visage Ease Pro, which enables remote interpretation of diagnostic imaging studies stored on a Visage 7 server. Key product brands include Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
4/7

The average target price of PME.AX is 192 and suggests 7.55% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.08.2026 16:01

Small caps last week: Playboy's pivot, AbCellera trial win, GLP-1 boon for AirSculpt

15.08.2026 13:01

A New Leader from China, Billionaires in Soccer, and Ray Dalio's Party

15.08.2026 03:06

Alphabet, Delta, and Construction: Where Buffett's Successor Invested

15.08.2026 02:58

Shares of U.S. drone manufacturers surged following Trump's new tariffs

15.08.2026 02:44

The market is unfazed by the stock decline: Wall Street's fear index is at its lowest level since December

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026